Disease Landscape and Forecast Insights

In 2022, sales of branded biologics in immunology exceeded $67 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…

In 2022, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $150 billion in the major pharmaceutical markets under…

In 2022, sales of branded biologics in ophthalmology exceeded $9.8 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast period…

Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…

In 2022, sales of branded biologics for respiratory indications totaled about $2.3 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032…

In 2022, sales of insulins at the ex-manufacturer price level exceeded $16 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast…

Asthma is a common chronic airway disease that affects children and adults. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK’s Advair /…

In 2022, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $3.6 billion in the major pharmaceutical markets under study (…

The osteoporosis therapy market is expected to experience rapid growth over the forecast period owing to the increasing prevalence of postmenopausal osteoporosis disease and the increasing uptake…

The treatment of neuropathic pain involves the use of drugs from several classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…

In 2023, Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation associated with Alzheimer’s disease (AD). Other novel agents are now emerging as potential treatments…